Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

Pediatric central nervous system hemangioblastomas: different from adult forms? A retrospective series of 25 cases.

Cheng J, Liu W, Hui X, Zhang S, Ju Y.

Acta Neurochir (Wien). 2017 Jul 27. doi: 10.1007/s00701-017-3275-0. [Epub ahead of print]

PMID:
28752202
2.
3.

Intraosseous hemangioblastoma of the cervical spine: case report.

Li Z, Curtis B, Layser R, Selvarajan SK, Harrop J, Kenyon LC, Parsons T, Rubin A.

J Neurosurg Spine. 2017 Jun 30:1-4. doi: 10.3171/2017.3.SPINE1622. [Epub ahead of print]

PMID:
28665246
4.

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.

Albiñana V, Escribano RMJ, Soler I, Padial LR, Recio-Poveda L, Villar Gómez de Las Heras K, Botella LM.

Orphanet J Rare Dis. 2017 Jun 29;12(1):122. doi: 10.1186/s13023-017-0664-7.

5.

Neuroprotective effects respond to cerebral ischemia without susceptibility to HB-tumorigenesis in VHL heterozygous knockout mice.

Wang Y, Yang J, Du G, Ma D, Zhou L.

Mol Carcinog. 2017 Jun 2. doi: 10.1002/mc.22688. [Epub ahead of print]

PMID:
28574654
6.

CNS hemangioblastomatosis in a patient without von Hippel-Lindau disease.

Franco A, Pytel P, Lukas RV, Chennamaneni R, Collins JM.

CNS Oncol. 2017 Apr;6(2):101-105. doi: 10.2217/cns-2016-0027.

PMID:
28425756
7.

A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS.

Bao L, Al-Assar O, Drynan LF, Arends MJ, Tyers P, Barker RA, Rabbitts TH.

Sci Rep. 2017 Mar 21;7:44899. doi: 10.1038/srep44899.

8.

[Extradural spinal cord hemangioblastoma (a case report and literature review)].

Konovalov NA, Shishkina LV, Asyutin DS, Onoprienko RA, Korolishin VA, Zakirov BA, Martynova MA, Cherkiev IU, Pogosyan AL, Timonin SY.

Zh Vopr Neirokhir Im N N Burdenko. 2016;80(6):88-92. doi: 10.17116/neiro201680688-92. Review. Russian.

PMID:
28139578
9.

Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.

Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Pacak K, Zhuang Z, Chittiboina P.

Sci Rep. 2017 Jan 17;7:40822. doi: 10.1038/srep40822.

10.

Expression of angiopoietins in central nervous system hemangioblastomas is associated with cyst formation.

Li X, Liu W, Liu J, Wang W, Zhang S, Chen J, Hui X.

Neurosci Lett. 2017 Feb 3;639:120-125. doi: 10.1016/j.neulet.2016.12.066. Epub 2016 Dec 29.

PMID:
28041961
11.

Von Hippel-Lindau disease: the clinical manifestations and genetic analysis results of two cases from a single family.

Kinyas S, Ozal SA, Guclu H, Gurlu V, Esgin H, Gurkan H.

Balkan J Med Genet. 2016 Jul 9;18(2):65-70. eCollection 2015 Dec 1.

12.

Survival and causes of death in patients with von Hippel-Lindau disease.

Binderup ML, Jensen AM, Budtz-Jørgensen E, Bisgaard ML.

J Med Genet. 2017 Jan;54(1):11-18. doi: 10.1136/jmedgenet-2016-104058. Epub 2016 Aug 18.

PMID:
27539272
13.

Personalized Medicine for Nervous System Manifestations of von Hippel-Lindau Disease.

Schunemann V, Huntoon K, Lonser RR.

Front Surg. 2016 Jun 30;3:39. doi: 10.3389/fsurg.2016.00039. eCollection 2016. Review.

14.

Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.

Lee JS, Lee JH, Lee KE, Kim JH, Hong JM, Ra EK, Seo SH, Lee SJ, Kim MJ, Park SS, Seong MW.

BMC Med Genet. 2016 Jul 20;17(1):48. doi: 10.1186/s12881-016-0306-2.

15.

Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome.

Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER, Richard S, Giles RH.

J Clin Oncol. 2016 Jun 20;34(18):2172-81. doi: 10.1200/JCO.2015.65.6140. Epub 2016 Apr 25. Review.

PMID:
27114602
16.

Hemangioblastomas with leptomeningeal dissemination: case series and review of the literature.

Koo HW, Park JE, Cha J, Kim DJ, Kang SG, Lim SC, Suh DC.

Acta Neurochir (Wien). 2016 Jun;158(6):1169-78. doi: 10.1007/s00701-016-2798-0. Epub 2016 Apr 12.

PMID:
27068045
17.

Von Hippel-Lindau disease: an evaluation of natural history and functional disability.

Feletti A, Anglani M, Scarpa B, Schiavi F, Boaretto F, Zovato S, Taschin E, Gardi M, Zanoletti E, Piermarocchi S, Murgia A, Pavesi G, Opocher G.

Neuro Oncol. 2016 Jul;18(7):1011-20. doi: 10.1093/neuonc/nov313. Epub 2016 Jan 12.

18.

Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease.

Huntoon K, Wu T, Elder JB, Butman JA, Chew EY, Linehan WM, Oldfield EH, Lonser RR.

J Neurosurg. 2016 Apr;124(4):971-6. doi: 10.3171/2015.4.JNS1533. Epub 2015 Oct 30.

19.

Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Taïeb D, Barlier A, Yang C, Pertuit M, Tchoghandjian A, Rochette C, Zattara-Canoni H, Figarella-Branger D, Zhuang Z, Pacak K, Metellus P.

J Neurooncol. 2016 Feb;126(3):473-81. doi: 10.1007/s11060-015-1983-y. Epub 2015 Oct 29.

PMID:
26514359
20.

Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.

Migliorini D, Haller S, Merkler D, Pugliesi-Rinaldi A, Koka A, Schaller K, Leemann B, Dietrich PY.

CNS Oncol. 2015;4(6):387-92. doi: 10.2217/cns.15.22. Epub 2015 Oct 26. Review.

PMID:
26497655

Supplemental Content

Loading ...
Support Center